COZART RAPISCAN ORAL FLUID DRUG TEST - OPIATE/METHADONE— 510(k) K020920

Name: FDA 510(k) clearance K020920
Creator: U.S. Food and Drug Administration
Published: 2002-11-05

Substantially Equivalent

Cozart Bioscience , Ltd.

FDA 510(k) clearance K020920 for COZART RAPISCAN ORAL FLUID DRUG TEST - OPIATE/METHADONE, Substantially Equivalent on 2002-11-05. Applicant: Cozart Bioscience , Ltd.. Device class: 2.

Clearance details

Applicant: Cozart Bioscience , Ltd.
Product code: Code DJG
Device class: Class 2
Regulation: 21 CFR 862.3650
Advisory panel: Clinical Toxicology
Date received: 2002-03-21
Decision date: 2002-11-05
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Oxfordshire Ox14 4ru, GB

Download summary PDF View on FDA.gov ↗

Recent devices under product code DJG

view all

K252684 — Labcorp Fentanyl Urine Visual Test2026-01-29
K250741 — Evidence MultiSTAT DOA Urine MultiPlex2026-01-23
K253082 — LZI Buprenorphine II Enzyme Immunoassay2026-01-16
K252520 — SEFRIA Hydrocodone Oral Fluid2025-09-11
K251972 — Healgen® AccuFluor Fentanyl Fluorescence Immunoassay (FIA)Test Kit - Qualitative +1 more2025-08-15

More clearances from Cozart Bioscience , Ltd.

view all

K033743 — COZART EIA AMPHETAMINES ORAL FLUID MICROPLATE KIT2004-06-03
K021944 — COZART EIA COTININE URINE KIT2003-05-14
K030234 — COZART EIA COCAINE ORAL FLIUD KIT2003-04-28
K024339 — COZART EIA OPIATES ORAL FLUID KIT2003-04-07
K011131 — METHADONE MICROPLATE EIA URINE APPLICATION2001-07-31

Data sourced from openFDA. This site is unofficial and independent of the FDA.